by McBride A, Quang Chanh H, Trung Trieu H, Bang Tran H, Anderson KB, Aogo RA, Avirutnan P, Hoai Bao Tran L, Hui Chan X, Chandra R,7 Chang A, Ying Chia P, Daniel V, Demidova A, Rodriguez MPC, Figueiredo-Mello C, Garcia-Gallo E, Garrood W, Thi Hoai Tam D, Jaenisch T, Kain M, Katzelnick L, Khanh Lam P, Leopold SJ, Lim C, Siqueira AM, Malavige GN, Malik S, Merson L, Meyer-Andrieux I, Moorman N, Neal A, Minh Nguyen N, Ong H-C, Pett S, Rojas-Garrido E, Schilling W, Shahrin L, Sjö P, Faridah Syed Omar S, Teixeira M, Kumar Tirupakuzhi Vijayaraghavan B, Villar L, Lam Vuong N, Waickman A, Wills B, Kestelyn E, Watson J, Borisovich Munblit D, Yacoub S. BMJ Global Heallth 2026;4:e004043. doi: 10.1136/bmjph-2025-004043
Summary: The authors of this article report on a meeting of the Dengue Therapeutics Consortium. They summarise the state of dengue therapeutics research and highlight steps to ensure patients have equitable access to affordable, effective treatments. They review the antiviral pipeline and propose methods to rapidly screen for activity prior to larger Phase III trials. They review ongoing Phase II and III trials to evaluate repurposed host-directed therapies for patients with moderate and severe disease and suggest considerations for future trial design. They conclude that multisectoral collaboration is essential to achieve effective treatments, including drug development aligned to target product profiles, clinical trial endpoints acceptable to patients and regulators, and sustained commitment from all parties to ensure effective treatments reach patients.
